January 1, 2012Open Access

Progression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

In an advanced cancer population of diverse tumor types, we observe a statistically significant decrease in PFS with each successive standard therapy. Identification of new therapies that reverse this trend of decreasing PFS may lead to improved clinical outcomes.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Bailey et al. (Sun,) studied this question.

synapsesocial.com/papers/69dd5079fb7610310c102001 https://doi.org/https://doi.org/10.7150/jca.3.7

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil2008 · 96 citations
2Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer2010 · 59 citations
3Pooled Survival and Response Data From Phase III Randomized Controlled Trials for Gemcitabine-based Regimes in the Treatment of Advanced Pancreatic Cancer2011 · 28 citations
4Targeted cancer therapies2011 · 3 citations
5Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study2010 · 417 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo